BCRX
Price
$8.93
Change
+$0.22 (+2.53%)
Updated
May 2 closing price
Capitalization
1.87B
2 days until earnings call
COGT
Price
$5.88
Change
+$0.25 (+4.44%)
Updated
May 2, 04:59 PM (EDT)
Capitalization
668.34M
10 days until earnings call
Ad is loading...

BCRX vs COGT

Header iconBCRX vs COGT Comparison
Open Charts BCRX vs COGTBanner chart's image
BioCryst Pharmaceuticals
Price$8.93
Change+$0.22 (+2.53%)
Volume$4.42M
Capitalization1.87B
Cogent Biosciences
Price$5.88
Change+$0.25 (+4.44%)
Volume$42.43K
Capitalization668.34M
BCRX vs COGT Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. COGT commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and COGT is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (BCRX: $8.93 vs. COGT: $5.87)
Brand notoriety: BCRX: Notable vs. COGT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 122% vs. COGT: 72%
Market capitalization -- BCRX: $1.87B vs. COGT: $668.34M
BCRX [@Biotechnology] is valued at $1.87B. COGT’s [@Biotechnology] market capitalization is $668.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.17B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileCOGT’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • COGT’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than COGT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 6 TA indicator(s) are bullish while COGT’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 6 bullish, 4 bearish.
  • COGT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than COGT.

Price Growth

BCRX (@Biotechnology) experienced а +6.44% price change this week, while COGT (@Biotechnology) price change was +26.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

COGT is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.87B) has a higher market cap than COGT($668M). BCRX YTD gains are higher at: 18.750 vs. COGT (-24.744). BCRX has higher annual earnings (EBITDA): 12.8M vs. COGT (-271.59M). BCRX has more cash in the bank: 321M vs. COGT (287M). COGT has less debt than BCRX: COGT (17.5M) vs BCRX (809M). BCRX has higher revenues than COGT: BCRX (451M) vs COGT (0).
BCRXCOGTBCRX / COGT
Capitalization1.87B668M280%
EBITDA12.8M-271.59M-5%
Gain YTD18.750-24.744-76%
P/E RatioN/AN/A-
Revenue451M0-
Total Cash321M287M112%
Total Debt809M17.5M4,623%
FUNDAMENTALS RATINGS
BCRX vs COGT: Fundamental Ratings
BCRX
COGT
OUTLOOK RATING
1..100
2315
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
6470
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3891
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for COGT (81) in the Miscellaneous industry. This means that BCRX’s stock grew somewhat faster than COGT’s over the last 12 months.

BCRX's Profit vs Risk Rating (64) in the Biotechnology industry is in the same range as COGT (70) in the Miscellaneous industry. This means that BCRX’s stock grew similarly to COGT’s over the last 12 months.

COGT's SMR Rating (96) in the Miscellaneous industry is in the same range as BCRX (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for COGT (91) in the Miscellaneous industry. This means that BCRX’s stock grew somewhat faster than COGT’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as COGT (100) in the Miscellaneous industry. This means that BCRX’s stock grew similarly to COGT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXCOGT
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 25 days ago
80%
Bearish Trend 25 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TFSCX15.85N/A
N/A
Templeton Ins Foreign Smaller Co Ser Adv
PAVLX43.78N/A
N/A
T. Rowe Price Value Adv
IRMCX10.70N/A
N/A
Voya Russell Mid Cap Index Port S
FWBTX13.72N/A
N/A
Fidelity Advisor Multi-Asset Income C
GSAJX14.18N/A
N/A
Goldman Sachs Small Cap Growth Instl

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
+4.26%
SPHDF - COGT
63%
Loosely correlated
N/A
ETNB - COGT
51%
Loosely correlated
+7.38%
ARWR - COGT
49%
Loosely correlated
+2.71%
XNCR - COGT
48%
Loosely correlated
+3.68%
CRNX - COGT
47%
Loosely correlated
+0.72%
More